Day: May 4, 2020

— Veteran Industry Executive and Anesthesiologist Brings Significant Clinical and Commercial Experience in Pain Management —PARSIPPANY, N.J., May 04, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announces the appointment of Donald C. Manning, M.D., Ph.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Manning, who brings more than 20 years of experience in biopharmaceutical executive leadership, was most recently, Chief Medical Officer at Adynxx, Inc., a development company focused on advancing disease-modifying products for the treatment of pain management and inflammation. In his new position, Dr. Manning will report directly to David Stack, chairman and chief executive officer of Pacira BioSciences. “We...

TORONTO, May 04, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan” or the “Trust”) (TSX: REI.UN) announced today its plans to enhance the shopping experience at its centres across Canada by launching RioCan Curbside Collect™ (“Curbside Collect”), a safe and convenient way for retail tenants and consumers to transact as businesses re-open.Curbside Collect is a new RioCan initiative designed to respond to the evolving retail landscape that offers designated areas for customers to easily access their pre-ordered items from participating stores at applicable RioCan centres in a contactless way. The program is intended to assist businesses to safely ramp back up and serve returning customers as the various levels of government begin to ease restrictions on business closures during the COVID-19 outbreak. Longer term,...

YAVNE, Israel, May 04, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.NexoBrid, currently approved in the European Union and other international markets, is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns. Commercialization of NexoBrid...

VANCOUVER, British Columbia, May 04, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is excited to announce that it has entered into a non-binding Letter of Intent (“LOI”) with Save-On-Foods and separately with Pure Integrative Pharmacy to pilot telemedicine kiosks in nine stores throughout British Columbia.For 6 weeks starting on May 26, 2020, CloudMD’s telemedicine software and services will be offered free of charge to Save-On-Foods and Pure Integrative Pharmacy clients. Telemedicine kiosks will be installed in existing private consult rooms in participating Save-On-Foods and Pure Integrative Pharmacy locations across BC. Patients will be able to see a doctor for prescription...

Constructive End of Phase 2 Meeting with FDA for Status Epilepticus Completed in March; Pivotal Phase 3 Clinical Trial Expected to Begin Next QuarterTopline Data on Track for Q3 2020 from Pivotal Phase 3 Marigold Study in CDKL5 Deficiency Disorder and Preparations Continue for Potential NDA FilingFirst Patients to be Screened this Quarter for Phase 2 Tuberous Sclerosis Complex Clinical TrialRADNOR, Pa., May 04, 2020 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2020.“We are proud to have made real progress across all of our clinical programs prior to and during the...

FuelCell Energy’s Power Platform Will Create a Cleaner Energy Profile for the City of San BernardinoRenewable Power Produced by the Fuel Cell will Contribute to California’s Decarbonization ObjectivesProprietary FuelCell Technology Drives Reduction in Particulates, NOx and SOx Following the Commercial Operation Date, FuelCell Energy Will Provide Low-Carbon Power Under a 20 Year Power Purchase Agreement To Supply San Bernardino Municipal Water DepartmentConstruction Financing Provided By Existing Orion Energy Partners Credit AgreementFuelCell Energy’s SureSource 1500 is the Only Fuel Cell Power Platform Certified by CARB for Operation on Biogas under the CARB 2013 Distributed Generation Emission Standards    DANBURY, Conn., May 04, 2020 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) — a global leader in fuel cell technology–with...

WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended March 31, 2020.“We are pleased to report that we are approaching the conclusion of the double-blind, 12-week phase of our pivotal Phase 3 trial with roluperidone and reiterate our previous guidance that we expect to report top line results in the second quarter,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Progress in this trial has been unaffected to date by the coronavirus pandemic and we are continually monitoring each trial site and our contract research organizations to ensure the safety...

DENVER, May 04, 2020 (GLOBE NEWSWIRE) — RLH Corporation (NYSE:RLH) announced today that it will release its first quarter 2020 results on Friday, May 8, 2020 before the open of the market.  Red Lion’s senior management team plans to host a webcast and conference call to review its financial results at 9:00 a.m. ET the same day.WEBCAST INFORMATIONThe live webcast can be accessed through the Investor Relations section of the Company’s website http://ir.redlion.com/events-and-presentations/events. The Company encourages use of the webcast due to potential extended wait times to access the conference call via dial-in.    CONFERENCE CALLFor those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 877-407-8289 or 201-689-8341, respectively, and requesting the Red Lion Hotel...

NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver liquidity to the global markets and provide execution services and data, analytics and connectivity products, today announced it has appointed Mr. Brett Fairclough and Mr. Joseph Molluso as Co-Presidents and Co-Chief Operating Officers of Virtu Financial.  Mr. Molluso will re-join Virtu after a brief period away from the company.Mr. Fairclough was promoted to Chief Operating Officer and Global Head of Business Development at Virtu in September of 2019, where he has worked since 2007. He led our Asia Pacific operations from 2014-2019 and was the Chief Compliance Officer of Virtu’s broker-dealer subsidiaries from 2012-2014.“Since assuming his expanded...

On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesAdded new potential CHF 60 million Phase 2 initiation milestone for the small molecule Morphomer™ Tau aggregation inhibitor program and received CHF 10 million milestone in Q1 2020 in Lilly partnershipAdvanced a lead anti-alpha-synuclein therapeutic antibody candidate into preclinical development based on new proof-of-concept data presented at AAT-AD/PDTMLAUSANNE, Switzerland, May 04, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced...